New Hope for Alzheimer’s: Two FDA-Approved Drugs, GLP‑1 Research, and a Controversial Surgical Claim

After decades of slow progress, Alzheimer’s research is gathering momentum. Two FDA-authorized drugs, lecanemab and donanemab , reduce amyloid plaques and slow cognitive decline modestly. Scientists are expandi...



























